Bio-Thera Solutions announce first patient dosed in Phase 3 clinical Trial for BAT8006, an Antibody Drug Conjugate targeting folate receptor α for the treatment of platinum-resistant ovarian cancer

CAR-T Digest - August 2020

Weekly Digest - June 2025

25 June 2025: Bio-Thera Solutions announce first patient dosed in Phase 3 clinical trial for BAT8006, an Antibody Drug Conjugate targeting folate receptor α for the treatment of platinum-resistant ovarian cancer

Bio-Thera Solutions has initiated a Phase 3 trial for BAT8006, an ADC targeting folate receptor α in platinum-resistant ovarian cancer
In a Phase 1/2 study, BAT8006 showed a median PFS of 7.63 months, ORR of 40.7%, and DCR of 80.5% without interstitial lung disease or ocular toxicity
Platinum-resistant ovarian cancer has poor prognosis, with limited therapies—only one FRα-targeting ADC approved globally, restricted to high FRα expression patients and linked to ocular toxicity
BAT8006 is among the first FRα-targeting ADCs in China to enter pivotal Phase 3 trials, aiming to treat patients regardless of FRα expression levels
The trial’s goal is to compare BAT8006 with investigator’s choice chemotherapy, potentially offering a broader and safer treatment alternative